Medicines and Healthcare products Regulatory Agency

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. European Medicines Agency荷兰13
2. Uppsala Monitoring Centre瑞典9
3. Netherlands Pharmacovigilance Centre Lareb荷兰5
4. GlaxoSmithKline (United Kingdom)英国5
5. AstraZeneca (United Kingdom)英国5
6. Erasmus MC荷兰4
7. Agency for Medicinal Products and Medical Devices of Croatia克罗地亚4
8. Novartis (Switzerland)瑞士4

按月发文

逐年被引

最新文献

1. 1
   Recommendations to Enable Broader Use of Real‐World Evidence to Inform Decision‐Making Throughout Pharmacovigilance Signal ManagementPharmacoepidemiology and Drug Safety20255
2. 2
   Implementation and Results of Active Vaccine Safety Monitoring During the COVID-19 Pandemic in the UK: A Regulatory PerspectiveDrug Safety20253
3. 3
   Empowering African Expertise: Enhancing Safety Data Integration and Signal Detection for COVID-19 Vaccines Through the African Union Smart Safety Surveillance Joint Signal Management GroupDrug Safety20252
4. 4
   Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of FluoroquinolonesPharmacoepidemiology and Drug Safety20245
5. 5
   Sharing Is Caring? International Society for Pharmacoepidemiology Review and Recommendations for Sharing Programming CodePharmacoepidemiology and Drug Safety20249
6. 6
   Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative StudyDrug Safety202319
7. 7
   Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UKDrug Safety202114
8. 8
   Risk Management for the 21st Century: Current Status and Future NeedsDrug Safety202126
9. 9
   Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADRDrug Safety201986
10. 10
    A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in childrenPharmacoepidemiology and Drug Safety201920

高被引文献

1. 1
   Good Signal Detection Practices: Evidence from IMI PROTECTDrug Safety2016152
2. 2
   Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting DatabasesDrug Safety2015149
3. 3
   Promoting and Protecting Public Health: How the European Union Pharmacovigilance System WorksDrug Safety2017143
4. 4
   Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADRDrug Safety201986
5. 5
   Medication Errors: New EU Good Practice Guide on Risk Minimisation and Error PreventionDrug Safety201678
6. 6
   Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?Drug Safety201674
7. 7
   Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous DatabasesDrug Safety201660
8. 8
   Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADRDrug Safety201954
9. 9
   Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic DrugsDrug Safety201743
10. 10
    Establishing a Framework for the Use of Social Media in Pharmacovigilance in EuropeDrug Safety201936

主要发表期刊

研究主题